Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Executive Committee
Partners
Scientific Advisory Board
Perspectives
Pipeline
Overview
ADP-A2M10 (MAGE-A10)
ADP-A2M4 (MAGE-A4)
ADP-A2AFP (AFP)
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Taking Part in our Clinical Trials
Clinical Trial FAQ
Cancer Information
Cancer Immunotherapy Month
News & Events
News
Scientific Conferences
Investor Conferences
Investors
Our CEO’s perspective on our FY2018 Update
Click Here
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Investigating SPEAR T-Cell Therapy in 10 Solid Tumors
Learn More
Working with Leading Experts to Transform T-cell Therapy for Cancer Patients
Learn More
Latest News •
View all
February 27, 2019
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
February 27, 2019
Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
February 7, 2019
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
Perspectives
